CDK2 and melanoma: The conditional knockdown of CDK2 sensitizes the cells to Hsp90i (Fig 3C, left panel) and BRAFi (Fig 3C, right panel) treatments (Fig EV4F), clearly showing that CDK2 is a key player underlying melanoma resistance to both Hsp90i and BRAFi.